Denali Therapeutics Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics or view top-rated stocks.

Wall Street analysts have given Denali Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Denali Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Denali Therapeutics.

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.14. The business had revenue of $22.94 million for the quarter, compared to analyst estimates of $27.92 million. Denali Therapeutics had a trailing twelve-month return on equity of 5.31% and a net margin of 15.66%. The company's revenue was up 292.3% compared to the same quarter last year.
View Denali Therapeutics' earnings history.

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DNLI shares have increased by 204.8% and is now trading at $51.45.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued 12 month price objectives for Denali Therapeutics' shares. Their forecasts range from $50.00 to $105.00. On average, they expect Denali Therapeutics' stock price to reach $81.63 in the next twelve months. This suggests a possible upside of 58.6% from the stock's current price.
View analysts' price targets for Denali Therapeutics or view top-rated stocks among Wall Street analysts.

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Denali Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), Repligen (RGEN), Novavax (NVAX), argenx (ARGX), QIAGEN (QGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Exelixis (EXEL), Beam Therapeutics (BEAM), Halozyme Therapeutics (HALO) and Twist Bioscience (TWST).
View all of DNLI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (12.50%), Vanguard Group Inc. (6.28%), BlackRock Inc. (5.78%), Price T Rowe Associates Inc. MD (4.03%), FMR LLC (2.19%) and State Street Corp (1.91%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics.

DNLI stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vanguard Group Inc., Marshall Wace North America L.P., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Mark Asset Management LP, Cubist Systematic Strategies LLC, and Man Group plc. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics or view top insider-selling stocks.

DNLI stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Invesco Ltd., State Street Corp, Geode Capital Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Denali Therapeutics or or view top insider-buying stocks.

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNLI stock can currently be purchased for approximately $51.45.

Denali Therapeutics has a market capitalization of $6.26 billion and generates $335.66 million in revenue each year. The company earns $71.14 million in net income (profit) each year or $0.63 on an earnings per share basis.

Denali Therapeutics employs 291 workers across the globe.

The official website for Denali Therapeutics is www.denalitherapeutics.com.

Denali Therapeutics is headquartered at 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].